Industry Verticals »

All Categories

Insights »

About TMR »

Geriatric Medicines Market

Geriatric Medicines Market (Therapeutic Category - Analgesic, Antihypertensive, Statins, Antidiabetic, Proton Pump Inhibitor, Anticoagulant, Antipsychotic and Antidepressant; Condition - Cardiovascular, Arthritis, Diabetes, Neurological, Cancer, Osteoporosis, Respiratory; Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019 - 2027

  • According to Transparency Market Research’s latest report on the global geriatric medicine market for the historical period 2017–2018 and forecast period 2019–2027, rise in chronic diseases, increase in governments and NGOs supports for elderly and technological advancement for medication assistance are projected to drive the global geriatric medicine market during the forecast period
  • According to the report, the global geriatric medicine market was valued at US$ 672.0 Bn in 2018 and is anticipated to expand at a CAGR of 6.9% from 2019 to 2027
fa global geriatric medicine market

Increase in global geriatric population and Surge in Programs by Governments and NGOs to support Elderly Patients: Key Drivers

  • Rise in geriatric population has led to an increase in the incidence and prevalence of chronic diseases. According to the World Health Organization (WHO), people over the age of 65 form the fastest-growing population segment globally. The proportion of the world's population over 60 years is expected to double from about 11% to 22% between 2000 and 2050.
  • Stroke is a leading cause of death in the U.S. According to the Centers for Disease Control and Prevention (CDC), stroke claims one fatality every 40 seconds in the U.S. and about 795,000 people become victims of stroke (85% acute ischemic) each year. About 610,000 of these are first or new strokes, and 185,000 are recurrent strokes.
  • The global geriatric medicines market is expanding at a significant growth rate due to increasing government support toward old people for their health, safety, and nursing care. For instance, The Federal Long-Term Care Insurance Program (FLTCIP) was established in 2002 and is insured by John Hancock Life & Health Insurance Company, sponsored by the U.S. Office of Personnel Management (OPM), and administered by Long Term Care Partners, LLC (LTCP). The program is available to uniformed service members, federal civilians, and certain qualified family members. Currently, the program covers over 267,000 enrollees. The program provides home nursing services, hospice facility services, durable medical equipment (such as hospital-style beds, walkers, and wheelchairs), homecare planning visits, an emergency medical response system, and home modifications (such as installing wheelchair ramps).

Technological Advancement for Medication Assistance Boost Market Growth

  • The elderly are presently able to manage their multiple prescription drugs problem owing to recent advances in technology. There are pill boxes with alarms that enable seniors to know what exact pill needs to be taken and when. Several companies are developing and selling smart pill bottles.
  • These pill bottles allow connecting their medications to doctors and pharmacies for data on how often patients are taking their medication. They also alert (like a text message or phone call) the elderly about the appropriate time to take their medication, in case they forget. Therefore, technological advancement in medical assistance is likely to drive geriatric medicine market globally

Side Effects in Elderly to Hamper Market

  • Elderly people are more sensitive to frequently used drugs such as benzodiazepines, NSAIDs, and opioids. High chances of adverse drug reaction (ADR) and overdose in the elderly can lead to uptake of other form of therapies (herbal medicines, Unani, physiotherapy etc.), which in turn is projected to hamper the geriatric medicines market

Global Geriatric medicine Market: Competitive Landscape

  • This report profiles major players in the global geriatric medicine market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The global geriatric medicine market is highly fragmented, with the presence of a number of international as well as regional players
  • Leading players operating in the global geriatric medicine market are
    • Pfizer, Inc.
    • Merck & Co., Inc.
    • AstraZeneca
    • Bristol-Myers Squibb Company
    • Novartis AG
    • Sanofi S.A.
    • GlaxoSmithKline plc Eli Lilly and Company
    • Abbott Laboratories
    • Boehringer Ingelheim GmbH 

Global Geriatric medicine Market: Key Developments

Key players in the global geriatric medicine market are engaged in regulatory approvals, technologically advanced products, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global geriatric medicine market. A few expansion strategies adopted by players operating in the global geriatric medicine market are:

  • In October 2018, The U.S. Food and Drug Administration approved Dupixent (dupilumab) as an add-on maintenance therapy in patients aged 12 years and older with an eosinophilic phenotype or with oral corticosteroid-dependent asthma
  • In June 2017, Eli Lilly and Company received approval from the U.S. FDA for Humalog Junior KwikPen. The prefilled Humalog Junior KwikPen can help make insulin injections easier to incorporate into everyday lives.
  • In April 2016, Astellas Pharma Inc. and Amgen Inc. announced the launch of Repatha in Japan. Repatha is a PCSK9 inhibitor to treat patients with familial hypercholesterolemia having a high risk of cardiovascular diseases.

The report on the global geriatric medicine market discussed individual strategies, followed by company profiles of manufacturers of geriatric medicine. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global geriatric medicine market.

Global Geriatric Medicine Market – Segmentation

Therapeutic Category

Analgesic

Antihypertensive

Statins

Antidiabetic

Proton Pump Inhibitor

Anticoagulant

Antipsychotic and Antidepressant

Others

Condition

Cardiovascular

Arthritis

Diabetes

Neurological

Cancer

Osteoporosis

Respiratory

Others

Distribution Channels

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Region

North America

Europe

Asia Pacific

Latin America

Middle East & Africa

Frequently Asked Questions

What is the total market worth of geriatric medicines market?

Geriatric medicines market to reach US$ 1142.8 Bn by 2027

What is the anticipated CAGR of the geriatric medicines market in the forecast period?

Geriatric medicines market to expand at a CAGR of 6.9% from 2019 to 2027

What are the key driving factors for the growth of the geriatric medicines market?

Geriatric medicines market is driven by rise in chronic diseases and and technological advancement for medication assistance

Which is the rising prominent segment in the geriatric medicines market?

The analgesic segment dominated the global geriatric medicine market and the trend is projected to continue during the forecast period

Who are the key players in the geriatric medicines market?

Key players in the global geriatric medicine market include Pfizer, Inc., Merck & Co., Inc., AstraZeneca, Bristol-Myers Squibb Company, Novartis AG

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Geriatric Medicine Market

    4. Market Overview

        4.1. Introduction

            4.1.1.  Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Geriatric Medicine Market Analysis and Forecast, 2017–2027

            4.4.1. Market Revenue Projections (US$ Mn)

    5. Key Insights

        5.1. Regulatory Scenario, by Region/Globally

        5.2. Pipeline Analysis

        5.3. Mergers & Acquisitions 

    6. Global Geriatric Medicine Market Analysis and Forecast, by Therapeutic Category

        6.1. Introduction & Definition

            6.1.1. Key Findings / Developments

        6.2. Global Geriatric Medicine Market Value Forecast, by Therapeutic Category, 2017–2027

            6.2.1. Analgesic

            6.2.2. Antihypertensive

            6.2.3. Statins

            6.2.4. Antidiabetic

            6.2.5. Proton Pump Inhibitor

            6.2.6. Anticoagulant

            6.2.7. Antipsychotic and Antidepressant

            6.2.8. Others

        6.3. Global Geriatric Medicine Market Attractiveness, by Therapeutic Category

    7. Global Geriatric Medicine Market Analysis and Forecast, by Condition

        7.1. Introduction & Definition

            7.1.1. Key Findings / Developments

        7.2. Global Geriatric Medicine Market Value Forecast, by Condition, 2017–2027

            7.2.1. Cardiovascular

            7.2.2. Arthritis

            7.2.3. Diabetes

            7.2.4. Neurological

            7.2.5. Cancer

            7.2.6. Osteoporosis

            7.2.7. Respiratory

            7.2.8. Others

        7.3. Global Geriatric Medicine Market Attractiveness, by Condition

    8. Global Geriatric Medicine Market Analysis and Forecast, by Distribution Channel

        8.1. Introduction & Definition

            8.1.1. Key Findings / Developments

        8.2. Global Geriatric Medicine Market Value Forecast, by Distribution Channel, 2017–2027

            8.2.1. Hospital Pharmacies

            8.2.2. Retail Pharmacies

            8.2.3. Online Pharmacies

        8.3. Global Geriatric Medicine Market Attractiveness, by Distribution Channel

    9. Global Geriatric Medicine Market Analysis and Forecast, by Region

        9.1. Key Findings

        9.2. Global Geriatric Medicine Market Value Forecast, by Region

            9.2.1. North America 

            9.2.2. Europe 

            9.2.3. Asia Pacific 

            9.2.4. Latin America 

            9.2.5. Middle East & Africa 

        9.3. Global Geriatric Medicine Market Attractiveness, by Region

    10. North America Geriatric Medicine Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. North America Geriatric Medicine Market Value (US$ Mn) Forecast, by Therapeutic Category, 2017–2027

            10.2.1. Analgesic

            10.2.2. Antihypertensive

            10.2.3. Statins

            10.2.4. Antidiabetic

            10.2.5. Proton Pump Inhibitor

            10.2.6. Anticoagulant

            10.2.7. Antipsychotic and Antidepressant

            10.2.8. Others

        10.3. North America Geriatric Medicine Market Value (US$ Mn) Forecast, by Condition, 2017–2027

            10.3.1. Cardiovascular

            10.3.2. Arthritis

            10.3.3. Diabetes

            10.3.4. Neurological

            10.3.5. Cancer

            10.3.6. Osteoporosis

            10.3.7. Respiratory

            10.3.8. Others

        10.4. North America Geriatric Medicine Market Value (US$ Mn) Forecast, by Distribution Channels, 2017–2027

            10.4.1. Hospital Pharmacies

            10.4.2. Retail Pharmacies

            10.4.3. Online Pharmacies

        10.5. North America Geriatric Medicine Market Value (US$ Mn) Forecast, by Country, 2017–2027

            10.5.1. U.S.

            10.5.2. Canada

        10.6. North America Geriatric Medicine Market Attractiveness Analysis 

            10.6.1. By Therapeutic Category

            10.6.2. By Condition

            10.6.3. By Distribution Channels

            10.6.4. By Country

    11. Europe Geriatric Medicine Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Europe Geriatric Medicine Market Value (US$ Mn) Forecast, by Therapeutic Category, 2017–2027

            11.2.1. Analgesic

            11.2.2. Antihypertensive

            11.2.3. Statins

            11.2.4. Antidiabetic

            11.2.5. Proton Pump Inhibitor

            11.2.6. Anticoagulant

            11.2.7. Antipsychotic and Antidepressant

            11.2.8. Others

        11.3. Europe Geriatric Medicine Market Value (US$ Mn) Forecast, by Condition, 2017–2027

            11.3.1. Cardiovascular

            11.3.2. Arthritis

            11.3.3. Diabetes

            11.3.4. Neurological

            11.3.5. Cancer

            11.3.6. Osteoporosis

            11.3.7. Respiratory

            11.3.8. Others

        11.4. Europe Geriatric Medicine Market Value (US$ Mn) Forecast, by Distribution Channels, 2017–2027

            11.4.1. Hospital Pharmacies

            11.4.2. Retail Pharmacies

            11.4.3. Online Pharmacies

        11.5. Europe Geriatric Medicine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

            11.5.1. Germany

            11.5.2. U.K.

            11.5.3. France

            11.5.4. Spain

            11.5.5. Italy

            11.5.6. Rest of Europe 

        11.6. Europe Geriatric Medicine Market Attractiveness Analysis 

            11.6.1. By Therapeutic Category

            11.6.2. By Condition

            11.6.3. By Distribution Channels

            11.6.4. By Country/Sub-region

    12. Asia Pacific Geriatric Medicine Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Asia Pacific Geriatric Medicine Market Value (US$ Mn) Forecast, by Therapeutic Category, 2017–2027

            12.2.1. Analgesic

            12.2.2. Antihypertensive

            12.2.3. Statins

            12.2.4. Antidiabetic

            12.2.5. Proton Pump Inhibitor

            12.2.6. Anticoagulant

            12.2.7. Antipsychotic and Antidepressant

            12.2.8. Others

        12.3. Asia Pacific Geriatric Medicine Market Value (US$ Mn) Forecast, by Condition, 2017–2027

            12.3.1. Cardiovascular

            12.3.2. Arthritis

            12.3.3. Diabetes

            12.3.4. Neurological

            12.3.5. Cancer

            12.3.6. Osteoporosis

            12.3.7. Respiratory

            12.3.8. Others

        12.4. Asia Pacific Geriatric Medicine Market Value (US$ Mn) Forecast, by Distribution Channels, 2017–2027

            12.4.1. Hospital Pharmacies

            12.4.2. Retail Pharmacies

            12.4.3. Online Pharmacies

        12.5. Asia Pacific Geriatric Medicine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

            12.5.1. China

            12.5.2. Japan

            12.5.3. India

            12.5.4. Australia & New Zealand

            12.5.5. Rest of Asia Pacific 

        12.6. Asia Pacific Geriatric Medicine Market Attractiveness Analysis 

            12.6.1. By Therapeutic Category

            12.6.2. By Condition

            12.6.3. By Distribution Channels

            12.6.4. By Country/Sub-region

    13. Latin America Geriatric Medicine Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Latin America Geriatric Medicine Market Value (US$ Mn) Forecast, by Therapeutic Category, 2017–2027

            13.2.1. Analgesic

            13.2.2. Antihypertensive

            13.2.3. Statins

            13.2.4. Antidiabetic

            13.2.5. Proton Pump Inhibitor

            13.2.6. Anticoagulant

            13.2.7. Antipsychotic and Antidepressant

            13.2.8. Others

        13.3. Latin America Geriatric Medicine Market Value (US$ Mn) Forecast, by Condition, 2017–2027

            13.3.1. Cardiovascular

            13.3.2. Arthritis

            13.3.3. Diabetes

            13.3.4. Neurological

            13.3.5. Cancer

            13.3.6. Osteoporosis

            13.3.7. Respiratory

            13.3.8. Others

        13.4. Latin America Geriatric Medicine Market Value (US$ Mn) Forecast, by Distribution Channels, 2017–2027

            13.4.1. Hospital Pharmacies

            13.4.2. Retail Pharmacies

            13.4.3. Online Pharmacies

        13.5. Latin America Geriatric Medicine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

            13.5.1. Brazil

            13.5.2. Mexico

            13.5.3. Rest of Latin America Latin America 

        13.6. Latin America Geriatric Medicine Market Attractiveness Analysis 

            13.6.1. By Therapeutic Category

            13.6.2. By Condition

            13.6.3. By Distribution Channels

            13.6.4. By Country/Sub-region

    14. Middle East & Africa Geriatric Medicine Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Middle East & Africa Geriatric Medicine Market Value (US$ Mn) Forecast, by Therapeutic Category, 2017–2027

            14.2.1. Analgesic

            14.2.2. Antihypertensive

            14.2.3. Statins

            14.2.4. Antidiabetic

            14.2.5. Proton Pump Inhibitor

            14.2.6. Anticoagulant

            14.2.7. Antipsychotic and Antidepressant

            14.2.8. Others

        14.3. Middle East & Africa Geriatric Medicine Market Value (US$ Mn) Forecast, by Condition, 2017–2027

            14.3.1. Cardiovascular

            14.3.2. Arthritis

            14.3.3. Diabetes

            14.3.4. Neurological

            14.3.5. Cancer

            14.3.6. Osteoporosis

            14.3.7. Respiratory

            14.3.8. Others

        14.4. Middle East & Africa Geriatric Medicine Market Value (US$ Mn) Forecast, by Distribution Channels, 2017–2027

            14.4.1. Hospital Pharmacies

            14.4.2. Retail Pharmacies

            14.4.3. Online Pharmacies

        14.5. Middle East & Africa Geriatric Medicine Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2027

            14.5.1. GCC Countries

            14.5.2. South Africa

            14.5.3. Rest of Middle East & Africa 

        14.6. Middle East & Africa Geriatric Medicine Market Attractiveness Analysis 

            14.6.1. By Therapeutic Category

            14.6.2. By Condition

            14.6.3. By Distribution Channels

            14.6.4. By Country/Sub-region

    15. Competition Landscape

        15.1. Market Player - Competition Matrix (by Tier and Size of companies)

        15.2. Company Profiles

            15.2.1. Pfizer, Inc.

                15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.1.2. Growth Strategies

                15.2.1.3. SWOT Analysis

            15.2.2. Merck & Co., Inc. 

                15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.2.2. Growth Strategies

                15.2.2.3. SWOT Analysis

            15.2.3. AstraZeneca 

                15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.3.2. Growth Strategies

                15.2.3.3. SWOT Analysis

            15.2.4. Bristol-Myers Squibb Company 

                15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.4.2. Growth Strategies

                15.2.4.3. SWOT Analysis

            15.2.5. Novartis AG

                15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.5.2. Growth Strategies

                15.2.5.3. SWOT Analysis

            15.2.6. Sanofi S.A. 

                15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.6.2. Growth Strategies

                15.2.6.3. SWOT Analysis 

            15.2.7. GlaxoSmithKline plc 

                15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.7.2. Growth Strategies

                15.2.7.3. SWOT Analysis

            15.2.8. Eli Lilly and Company 

                15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.8.2. Growth Strategies

                15.2.8.3. SWOT Analysis

            15.2.9. Abbott Laboratories 

                15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.9.2. Growth Strategies

                15.2.9.3. SWOT Analysis

            15.2.10. Boehringer Ingelheim GmbH

                15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                15.2.10.2. Growth Strategies

                15.2.10.3. SWOT Analysis

    List of Table

    Table 01: Major Causes of Death for Persons Aged 65 or Over, 2014 (Standardized Death Rates per 100,000 Inhabitants)

    Table 02: Healthcare Overview (2016 or latest available)

    Table 03: Global Geriatric Medicines Market Value (US$ Mn) Forecast, by Therapeutic Category, 2017–2017

    Table 04: Global Geriatric Medicines Market Value (US$ Mn) Forecast, by Condition, 2017–2017

    Table 05: Global Geriatric Medicines Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2017–2017

    Table 06: Global Geriatric Medicines Market Value (US$ Mn) Forecast, by Region, 2017–2017

    Table 07: North America Geriatric Medicines Market Value (US$ Mn) Forecast, by Therapeutic Category, 2017–2027

    Table 08: North America Geriatric Medicines Market Value (US$ Mn) Forecast, by Condition, 2017–2027

    Table 09: North America Geriatric Medicines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2017

    Table 10: North America Geriatric Medicines Market Value (US$ Mn) Forecast, by Country, 2017–2017

    Table 11: Europe Geriatric Medicines Market Value (US$ Mn) Forecast, by Therapeutic Category, 2017–2027

    Table 12: Europe Geriatric Medicines Market Value (US$ Mn) Forecast, by Condition, 2017–2027

    Table 13: Europe Geriatric Medicines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2017

    Table 14: Europe Geriatric Medicines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2017

    Table 15: Asia Pacific Geriatric Medicines Market Value (US$ Mn) Forecast, by Therapeutic Category, 2017–2027

    Table 16: Asia Pacific Geriatric Medicines Market Value (US$ Mn) Forecast, by Condition, 2017–2027

    Table 17: Asia Pacific Geriatric Medicines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2017

    Table 18: Asia Pacific Geriatric Medicines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2017

    Table 19: Latin America Geriatric Medicines Market Value (US$ Mn) Forecast, by Therapeutic Category, 2017–2027

    Table 20: Latin America Geriatric Medicines Market Value (US$ Mn) Forecast, by Condition, 2017–2027

    Table 21: Latin America Geriatric Medicines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2017

    Table 22: Latin America Geriatric Medicines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2017

    Table 23: Middle East & Africa (MEA) Geriatric Medicines Market Value (US$ Mn) Forecast, by Therapeutic Category, 2017–2027

    Table 24: Middle East & Africa (MEA) Geriatric Medicines Market Value (US$ Mn) Forecast, by Condition, 2017–2027

    Table 25: Middle East & Africa (MEA) Geriatric Medicines Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2017

    Table 26: Middle East & Africa (MEA) Geriatric Medicines Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2017

    List of Figure

    Figure 01: Global Geriatric Medicines Market Snapshot

    Figure 02: Global Geriatric Medicines Market Value (US$ Mn) Forecast and Y-o-Y Growth (%), 2017–2027

    Figure 04: Market Value Share By Condition (2018)

    Figure 06: Market Value Share By Region (2018)

    Figure 03: Market Value Share By Therapeutic Category (2018)

    Figure 05: Market Value Share By Distribution Channel (2018)

    Figure 07: Global Geriatric Medicines Market Value Share, by Therapeutic Category, 2018 and 2027

    Figure 08: Global Geriatric Medicines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027, by Analgesics

    Figure 09: Global Geriatric Medicines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027, by Antihypertensive

    Figure 10: Global Geriatric Medicines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027, by Statins

    Figure 11: Global Geriatric Medicines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027, by Antidiabetic

    Figure 12: Global Geriatric Medicines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027, by Proton Pump Inhibitor

    Figure 13: Global Geriatric Medicines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027, by Anticoagulant 

    Figure 14: Global Geriatric Medicines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027, by Antipsychotic and Antidepressant 

    Figure 15: Global Geriatric Medicines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027, by Others 

    Figure 16: Global Geriatric Medicines Market Value Share, by Condition, 2018 and 2027

    Figure 17: Global Geriatric Medicines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027, by Cardiovascular

    Figure 18: Global Geriatric Medicines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027, by Arthritis

    Figure 19: Global Geriatric Medicines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027, by Diabetes

    Figure 20: Global Geriatric Medicines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027, by Neurological 

    Figure 21: Global Geriatric Medicines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027, by Cancer

    Figure 22: Global Geriatric Medicines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027, by Osteoporosis 

    Figure 23: Global Geriatric Medicines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027, by Antipsychotic and Antidepressant 

    Figure 24: Global Geriatric Medicines Market Revenue (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2027, by Others 

    Figure 25: Global Geriatric Medicines Market Value Share Analysis, by Distribution Channel, 2018 and 2027

    Figure 26: Global Geriatric Medicines Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Hospital Pharmacies, 2017–2027

    Figure 27: Global Geriatric Medicines Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Retail Pharmacies, 2017–2027

    Figure 28: Global Geriatric Medicines Market Revenue (US$ Mn) and Y-o-Y Growth (%), by Online Pharmacies, 2017–2027

    Figure 29: Global Geriatric Medicines Market Value Share, by Region, 2018 and 2027

    Figure 30: North America Geriatric Medicines Market Value (US$ Mn) Forecast, 2017–2027

    Figure 31: North America Market Attractiveness Analysis, by Country

    Figure 32: North America Geriatric Medicines Market Value Share Analysis, by Therapeutic Category, 2018 and 2027

    Figure 33: North America Geriatric Medicines Market Value Share Analysis, by Condition, 2018 and 2027

    Figure 34: North America Geriatric Medicines Market Value Share Analysis, by Distribution Channel, 2018 and 2027

    Figure 35: North America Geriatric Medicines Market Value Share Analysis, by Country, 2018 and 2027

    Figure 36: Europe Geriatric Medicines Market Value (US$ Mn) Forecast, 2017–2027

    Figure 37: Europe Market Attractiveness Analysis, by Country/Sub-region

    Figure 38: Europe Geriatric Medicines Market Value Share Analysis, by Therapeutic Category, 2018 and 2027

    Figure 39: Europe Geriatric Medicines Market Value Share Analysis, by Condition, 2018 and 2027

    Figure 40: Europe Geriatric Medicines Market Value Share Analysis, by Distribution Channel, 2018 and 2027

    Figure 41: Europe Geriatric Medicines Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

    Figure 42: Asia Pacific Geriatric Medicines Market Value (US$ Mn) Forecast, 2017–2027

    Figure 43: Asia Pacific Market Attractiveness Analysis, by Country

    Figure 44: Asia Pacific Geriatric Medicines Market Value Share Analysis, by Therapeutic Category, 2018 and 2027

    Figure 45: Asia Pacific Geriatric Medicines Market Value Share Analysis, by Condition, 2018 and 2027

    Figure 46: Asia Pacific Geriatric Medicines Market Value Share Analysis, by Distribution Channel, 2018 and 2027

    Figure 47: Asia Pacific Geriatric Medicines Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

    Figure 48: Latin America Geriatric Medicines Market Value (US$ Mn) Forecast, 2017–2027

    Figure 49: Latin America Market Attractiveness Analysis, by Country

    Figure 50: Latin America Geriatric Medicines Market Value Share Analysis, by Therapeutic Category, 2018 and 2027

    Figure 51: Latin America Geriatric Medicines Market Value Share Analysis, by Condition, 2018 and 2027

    Figure 52: Latin America Geriatric Medicines Market Value Share Analysis, by Distribution Channel, 2018 and 2027

    Figure 53: Latin America Geriatric Medicines Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

    Figure 54: Middle East & Africa (MEA) Geriatric Medicines Market Value (US$ Mn) Forecast, 2017–2027

    Figure 55: Middle East & Africa (MEA) Market Attractiveness Analysis, by Country/Sub-region

    Figure 56: Middle East & Africa (MEA) Geriatric Medicines Market Value Share Analysis, by Therapeutic Category, 2018 and 2027

    Figure 57: Middle East & Africa (MEA) Geriatric Medicines Market Value Share Analysis, by Condition, 2018 and 2027

    Figure 58: Middle East & Africa (MEA) Geriatric Medicines Market Value Share Analysis, by Distribution Channel, 2018 and 2027

    Figure 59: Middle East & Africa (MEA) Geriatric Medicines Market Value Share Analysis, by Country/Sub-region, 2018 and 2027

    Figure 60: Pfizer, Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2018

    Figure 61: Pfizer, Inc. R&D Intensity (%) - Company Level or Segment Level, 2016–2018

    Figure 62: Pfizer, Inc. Breakdown of Net Sales, by Region, 2017

    Figure 63: Merck & Co., Inc. Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2018

    Figure 64: Merck & Co., Inc. R&D Intensity (%) - Company Level or Segment Level, 2016–2018

    Figure 65: Merck & Co., Inc. Break-up of Net Sales, by Region, 2017

    Figure 66: AstraZeneca Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2018

    Figure 67: AstraZeneca Breakdown of Net Sales, by Region, 2018

    Figure 68: AstraZeneca Marketing & Sales and R&D Expenses, 2016–2018

    Figure 69: Bristol-Myers Squibb Company Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2018

    Figure 70: Bristol-Myers Squibb Company R&D Intensity (%) - Company Level or Segment Level, 2016–2018

    Figure 71: Bristol-Myers Squibb Company Breakdown of Net Sales, by Region, 2018

    Figure 72: Novartis AG Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2018

    Figure 73: Novartis AG Marketing & Sales and R&D Expenses, 2016–2018

    Figure 74: Novartis AG Breakdown of Net Sales, by Business Segment, 2018

    Figure 75: Novartis AG Breakdown of Net Sales, by Region, 2018

    Figure 76: Sanofi S.A. Breakdown of Net Sales, by Region, 2018

    Figure 77: Sanofi S.A. Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2018

    Figure 78: Sanofi S.A. Breakdown of Net Sales, by Business Segment, 2018

    Figure 79: Sanofi S.A. R&D Intensity and Sales & Marketing Intensity (Pharmaceutical Segment) - Company Level, 2016–2018

    Figure 80: GlaxoSmithKline plc Revenue (US$ Bn) and Y-o-Y Growth (%), 2015–2018

    Figure 81: GlaxoSmithKline plc Marketing & Sales and R&D Expenses, 2016–2018

    Figure 82: GlaxoSmithKline plc Breakdown of Net Sales, by Business Segment, 2018

    Figure 83: GlaxoSmithKline plc Breakdown of Net Sales, by Region, 2018

    Figure 84: Eli Lilly and Company Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

    Figure 85: Eli Lilly and Company R&D Intensity (%) - Company Level or Segment Level, 2016–2018

    Figure 86: Eli Lilly and Company Breakdown of Net Sales, by Region, 2018

    Figure 87: Abbott Laboratories, Revenue (US$ Mn) and Y-o-Y Growth (%), 2016–2018

    Figure 88: Abbott Laboratories, Breakdown of Net Sales, by Business Segment, 2018

    Figure 89: Abbott Laboratories, Breakdown of Net Sales, by Region 2018

    Figure 90: Boehringer Ingelheim GmbH, Revenue (US$ Mn) and Y-o-Y Growth (%), 2015–2018

    Figure 91: Boehringer Ingelheim GmbH, Breakdown of Net Sales, by Business Segment, 2018

    Figure 92: Boehringer Ingelheim GmbH, Breakdown of Net Sales, by Region 2018

    Figure 93: Boehringer Ingelheim GmbH, R&D (US$ Mn) and Y-o-Y Growth (%), 2016–2018

Copyright © Transparency Market Research, Inc. All Rights reserved

Geriatric Medicines Market

Schedule a Call